tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2013 Jul;12(7):767-77. doi: 10.1586/14760584.2013.811178.
Clinical vaccine development for H5N1 influenza.
Clegg CH, Rininger JA, Baldwin SL.
Source
TRIA Bioscience Corp., Suite 250, 1616 Eastlake Avenue East, Seattle, WA 98102, USA. cclegg@triabio.com.
Abstract
H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations and there is great concern that this virus will begin to transmit between people and cause a global crisis. Vaccines are the cornerstone strategy for combating avian influenza but there are complex challenges for pandemic preparedness including the unpredictability of the vaccine target and the manufacturing requirement for rapid deployment. The less-than-optimal response against the 2009 H1N1 pandemic unmasked the limitations associated with influenza vaccine production and in 2010, the President's Council of Advisors on Science and Technology re-emphasized the need for new recombinant-based vaccines and adjuvants that can shorten production cycles, maximize immunogenicity and satisfy global demand. In this article, the authors review the efforts spent in developing an effective vaccine for H5N1 influenza and summarize clinical studies that highlight the progress made to date.
PMID:
23885822
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23885822
Clinical vaccine development for H5N1 influenza.
Clegg CH, Rininger JA, Baldwin SL.
Source
TRIA Bioscience Corp., Suite 250, 1616 Eastlake Avenue East, Seattle, WA 98102, USA. cclegg@triabio.com.
Abstract
H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations and there is great concern that this virus will begin to transmit between people and cause a global crisis. Vaccines are the cornerstone strategy for combating avian influenza but there are complex challenges for pandemic preparedness including the unpredictability of the vaccine target and the manufacturing requirement for rapid deployment. The less-than-optimal response against the 2009 H1N1 pandemic unmasked the limitations associated with influenza vaccine production and in 2010, the President's Council of Advisors on Science and Technology re-emphasized the need for new recombinant-based vaccines and adjuvants that can shorten production cycles, maximize immunogenicity and satisfy global demand. In this article, the authors review the efforts spent in developing an effective vaccine for H5N1 influenza and summarize clinical studies that highlight the progress made to date.
PMID:
23885822
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23885822